All In Biotech

Investigational drug · Phase 2

GDC-1261

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Prostate Cancer, Metastatic Prostate Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "GDC-1261"

First trial start

2026

Apr 29, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "GDC-1261", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Prostate Cancer
  • Metastatic Prostate Cancer

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "GDC-1261" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Prostate Cancer

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • XNW5004EZH2iPhase 37 trials

    Evopoint Biosciences Inc. · Relapsed/Refractory Peripheral T Cell Lymphoma, Advanced Prostate Cancer, Follicular Lymphoma, Grade 1

  • Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials

    Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

  • Teverelix DPPhase 23 trials

    Antev Ltd. · Acute Urinary Retention, Benign Prostate Hypertrophy(BPH), Endometriosis Pelvic

  • QLH12016Phase 22 trials

    Qilu Pharmaceutical Co., Ltd. · Prostatic Neoplasms, Advanced Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.